Cambrex Corporation (NYSE:CBM) has been given an average recommendation of “Buy” by the six research firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $65.67.

A number of brokerages recently issued reports on CBM. BidaskClub upgraded Cambrex Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Zacks Investment Research upgraded Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price objective for the company in a research note on Thursday, May 11th. Finally, ValuEngine downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd.

In related news, VP Samantha Hanley sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $57.56, for a total transaction of $805,840.00. Following the completion of the transaction, the vice president now directly owns 1,500 shares in the company, valued at approximately $86,340. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total value of $650,280.00. Following the transaction, the chief executive officer now owns 95,328 shares of the company’s stock, valued at $5,165,824.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 70,656 shares of company stock valued at $4,064,423. 2.48% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its position in Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares in the last quarter. Creative Planning boosted its position in Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares in the last quarter. Flinton Capital Management LLC boosted its position in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares in the last quarter. YorkBridge Wealth Partners LLC boosted its position in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in Cambrex Corporation during the first quarter worth approximately $109,000. Institutional investors own 98.28% of the company’s stock.

Shares of Cambrex Corporation (NYSE CBM) traded down 5.34% during midday trading on Tuesday, hitting $58.50. 1,285,934 shares of the stock were exchanged. The stock has a market cap of $1.91 billion, a P/E ratio of 22.27 and a beta of 2.28. Cambrex Corporation has a 52-week low of $38.30 and a 52-week high of $62.95. The firm’s 50 day moving average price is $58.97 and its 200-day moving average price is $55.37.

Cambrex Corporation (NYSE:CBM) last announced its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.76. The company had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. Cambrex Corporation had a return on equity of 24.92% and a net margin of 17.36%. The firm’s revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.68 EPS. On average, equities research analysts expect that Cambrex Corporation will post $3.02 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Cambrex Corporation (NYSE:CBM) Receives $65.67 Consensus PT from Brokerages” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/04/cambrex-corporation-nysecbm-receives-65-67-consensus-pt-from-brokerages.html.

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.